The Relation of TMPRSS2 Gene Polymorphism to COVID-19 Severity of Indonesian Population in Jakarta

Erlin Listiyaningsih; Rizkyana Avissa; Shinta Dewi Permata Sari; Wening Tri  Mawanti; Dewi Martalena

doi:10.22236/jbes/6310691

Erlin Listiyaningsih, Rizkyana Avissa, Shinta Dewi Permata Sari, Wening Tri Mawanti, Dewi Martalena

https://doi.org/10.22236/jbes/6310691

Issue
Vol. 6 No. 3 (2022): BIOEDUSCIENCE

Submitted
22 December 2022

Published
31 December 2022

Keywords:

COVID-19, Severity, SNP Genotyping, TMPRSS2

PDF

Abstract

Background: The COVID-19 disease caused by the SARS-CoV-2 virus has diverse symptoms, ranging from asymptomatic, mild symptoms such as flu-like illness and pneumonia to acute respiratory distress syndrome, which ends in death. Until now, the mechanism of the COVID-19 disease that causes widespread symptoms and the severity and factors that influence it are still unclear. During viral internalization, it needs to be cleaved by the serine protease encoded by the TMPRSS2 gene. It is hypothesized that higher expression of the TMPRSS2 gene causes higher virus internalization into cells, leading to more severe symptoms in patients. Methods: The Single Nucleotide Polymorphism Genotype Test was carried out to prove whether the TMPRSS2 gene affects the severity of COVID-19, as evidenced in other viral respiratory diseases. With a better understanding of gene expression related to this disease, it is hoped that we can better understand the mechanism of COVID-19 and establish better therapies and prevention against it. In this study, 68 COVID-19 patients participated and were categorized into two groups based on their clinical symptoms, namely mild symptoms without symptoms (n=12) and Moderate-Severe symptoms (n=56). PBMC cells were isolated from the patient. Then the DNA was extracted and used as a template in the SNP Genotyping of the TMPRSS2 rs2070788 gene variant. Results: The results showed that 35 samples had A/A homozygous genotypes, 29 A/G heterozygous samples, and 4 G/G homozygous samples. n=29) and heterozygous A/G (n=23), whereas only 4 were homozygous G/G. In addition, the homozygous G/G genotype was only detected in the moderate-severe group. Conclusions: A more significant number of samples from the asymptomatic mild symptom group is needed to statistically prove that homozygous G/G variants or G alleles are generally associated with the severity of COVID-19 patients.

Full text article

Generated from XML file

References

Andreade Clara Caldeira, Silva Ana Tercia Paulo, Vasconcelos Luydson Richardson Silva, Oliveira Pablo Rafael, Souza Carlos Dornels Freire De, Armstrong Anderson Da Costa, & Carmo Rodrigo Feliciano. (2022). A Polymorphism in the TMPRSS2 Gene Increases the Risk of Death in Older Patients Hospitalized With COVID-19. Journal of Viruses.
Asselta Rosanna, Paraboschi Elvezia Maria, Mantovani Alberto, & Duga Stefano. (2020). ACE2 and TMPRSS2 Variants and Expression as Candidates to Sex and Country Differences In COVID-19 Severity In Italy. National Center for Biotechnology Information, 12, 10087–10098.
Baughn Linda B, Sharma Neeraj, Elhaik Eran, Sekulic Aleksandar, Bryce Alan, & Fonesca Rafael. (2020). Targeting TMPRSS2 in SARS-CoV-2 Infection. Mayo Clinic Proceedings.
Cheng Zhongshan, Zhou Jie, Wang to Kelvin Kai, & et al. (2015). Identification of TMPRSS2 as a Susceptibility Gene for Severe 2009 Pandemic A(H1N1) Influenza and A(H7N9) Influenza. National Center for Biotechnology Information, 212.
David Alessia, Parkinson Nicholas, Peacock Thomas P, Castineira Erola Pairo, Khanna Tarun, Cobat Aurelie, Tenesa Albert, Shimizu Vanessa Sancho, Consortium Genomics, & Investigator ISARIC4C. (2022). A Common TMPRSS2 Variant Has a Protective Effect Against Severe COVID-19. Journal of Elsevier Masson France.
dbSNP Reference SNP (rs) Stand Orientation Reporting Updates. (2019, January 31). Https://Www.Ncbi.Nlm.Nih.Gov/Core/Assets/Snp/Docs/RefSNP_orientation_updates.Pdf.
Hoffmann Markus, Weber Hannah Kleine, Kruger Nadine, Muller Marcel, Drosten Cristian, & Pohlmann Stefan. (2020). The Novel Coronavirus 2019 (2019-nCoV) Uses The SARS Coronavirus Receptor ACE2 And the Cellular Protease TMPRSS2 For Entry Into Target Cells. Biorxiv Journal of Preprint Server for Biology.
Huang Chaolin, Wang Yeming, Li Xingwang, Ren Lili, Zhao Jianping, & Hu Yi. (2020). Clinical Features of Patients Infected With 2019 Novel Coronavirus In Wuhan, China. Journal of The Lancet Discovery Science, 395(10223), 497–506.
Irham Lalu Muhammad, Chou Wan Hsuan, Calkins Markus, Adikusuma Wirawan, Hsieh Shie Liang, & Chang Wei Chiao. (2020). Genetic variants that influence SARS-CoV-2 receptor TMPRSS2 expression among population cohorts from multiple continents. National Center for Biotechnology Information, 529, 263–269.
Liu Xiaoqing, Zhang Run, & He Guangsheng. (2020). Hematological Findings in Coronavirus Disease 2019: Indications of Progression Of Disease. National Center for Biotechnology Information, 99, 1421–1428.
Meng Bo, Abdullahi Adam, Ferreira Isabella, Goonawardane Niluka, Saito Akatsuki, Kimura Izumi, Yamasoba Daichi, Gerber Pehuen Pereyra, Fatihi Saman, & Rathore Surabhi. (2022). Altered TMPRSS2 Usage By SARS-CoV-2 Omicron Impacts Infectivity and Fusogenicity. Journal of Nature, 603.
Mollica Veronica, Rizzo Alessandro, & Messari Franceso. (2020). The Pivotal Role of TMPRSS2 In Coronavirus Disease 2019 And Prostate Cancer. Jouran Of Future Oncology.
Paniri Alireza, Hosseini Mohammad Mahdi, & Niaki Haleh Akhvan. (2020). First Comprehensive Computational Analysis of Functional Consequences of TMPRSS2 SNPs In Susceptibility To SARS-CoV-2 Among Different Populations. National Center for Biotechnology Information, 39, 3576–3593.
Rokni Mohsen, Nia Milad Heidari, Sarhadi Mohammad, Mirinejad Shekoufeh, Sargazi Saman, Moudi Mahdiyeh, Saravani Ramin, Rahdar Sara, & Kargar Maryam. (2022). Association of TMPRSS2 Gene Polymorphisms with COVID 19 Severity and Mortality: a Case Control Study with Computational Analyses. Journal of Biochemistry and Biotechnology.
Shang Jian, Wan Yushun, Luo Chuming, & Li Fang. (2020). Cell entry mechanisms of SARS-CoV-2. Journal Biological Science, 117.
Shapira Tirosh, Monreal I Abrrey, Dion Sebastien, Buchhloz David, Imbiakha Brian, Olmstead Andrea D, Jager Mason, Desilets Antoine, Gao Guang, & Martins Mathias. (2022). A TMPRSS2 Inhibitor Acts as a Pan-SARS-CoV-2 Prophylactic and Therapeutic. Journal of Nature, 605.
Stropes Jonathan, Chau Cindy H, & Figg William D. (2020). TMPRSS2: Potential Biomarker for COVID-19 Outcomes. The Journal of Clinical Pharmacology, 6(7).
Wan Yushun, Shang Jian, Graham Rachel, Baric Ralph S, & Li Fang. (2020). Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade Long Structural Studies of SARS Coronavirus. Journal of Virology, 94, 1–9.
Wulandari Laksmi, Hamidah Berliana, Pakpahan Cennikon, Damayanti Nevy Shinta, Kurniati Neneng Dewi, Adiatmaja Christophorus Oetama, Wigianita Monica Rizky, Soedarsono, Husada Dominicus, Tinduh Damayanti, Prakoeswa Cita Rosita Sigit, & Endaryanto Anang. (2021). Initial Study on TMPRSS2 p.Val160 Met Genetic Variant In COVID-19 Patients. Journal of Human Genomics.
Xu Jibao, Zhao Shizhe, Teng Tieshan, Abdalla Abualgasim Elgaili, Zhu Wan, Xie Longxiang, Wang Yunlong, & Guo Xiangqian. (2022). Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV. Journal of Virology, 12.
Zarubin Aleksei, Stepanov Vadim, Markov Anton, & et all. (2020). Structural Variability, Expression Profile, and Pharmacogenetic Properties of TMPRSS2 Gene as a Potential Target for COVID-19 Therapy. National Center for Biotechnology Information, 12(1).